Your session is about to expire
← Back to Search
Procedure
Therapeutic Hypothermia for Hearing Preservation During Cochlear Implants
N/A
Recruiting
Research Sponsored by Restorear Devices LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 18 years and older
Equal number of men and women
Must not have
Subjects under 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at initial cochlear implant activation or 1 month post-operatively; 3 and 12 months post-operatively
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to study the use of mild therapeutic hypothermia during cochlear implant surgery to see if it can help preserve any remaining hearing. They want to find out if it is safe and effective
Who is the study for?
This trial is for individuals undergoing cochlear implant surgery who are interested in trying a new method to preserve their remaining hearing. Specific eligibility details aren't provided, but typically participants must meet certain health standards and not have conditions that would exclude them from safely participating.
What is being tested?
The study is testing the safety and effectiveness of using mild therapeutic hypothermia during cochlear implant surgery. It involves comparing outcomes between patients receiving this cooling therapy and those who do not (control group).
What are the potential side effects?
While specific side effects are not listed, mild therapeutic hypothermia may include risks such as local discomfort or changes in ear sensation due to the cooling process.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
The study aims for an equal male and female participant ratio.
Select...
I have severe hearing loss that is not due to ear conditions.
Select...
I have been diagnosed with severe to profound hearing loss.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am under 18 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at initial cochlear implant activation or 1 month post-operatively; 3 and 12 months post-operatively
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at initial cochlear implant activation or 1 month post-operatively; 3 and 12 months post-operatively
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pure Tone Audiometry
Secondary study objectives
Electrically Evoked Compound Action Potential (ECAP)
Electrophysiological Impedance
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Safety StudyExperimental Treatment1 Intervention
Aim 1: Ascertain the safety of the system and device in patients undergoing cochlear implantation (CI). Mild therapeutic hypothermia will be delivered to the subjects during CI surgery via the ear canal.
Group II: Efficacy Study CoolingExperimental Treatment1 Intervention
Aim 2: Ascertain the applicability and efficacy of the device and system in patients undergoing cochlear implantation (CI). Half of the candidates will receive mild therapeutic hypothermia via the ear canal during cochlear implant surgery.
Group III: Efficacy Study ControlActive Control1 Intervention
Aim 2: Ascertain the applicability and efficacy of the device and system in patients undergoing cochlear implantation (CI). Half of the candidates will receive standard of care (no cooling) during cochlear implant surgery.
Find a Location
Who is running the clinical trial?
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
361 Previous Clinical Trials
182,004 Total Patients Enrolled
Restorear Devices LLCLead Sponsor
1 Previous Clinical Trials
116 Total Patients Enrolled
University of MiamiOTHER
955 Previous Clinical Trials
428,799 Total Patients Enrolled